Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients

Completed · Phase 2 · Has a placebo group

Conditions studied: Restless Legs Syndrome

In brief

To test the effectiveness and tolerability of Lyrica at various dose levels in RLS patients

Key facts

Study ID

NCT00676403

Run by

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

People needed

137

Starts

2008-04-01

Expected to finish

2009-01-01

Last updated by the study team

2021-02-10

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Moderate to severe idiopathic RLS
• symptoms occur predominantly in the evening
• symptoms interfere with sleep onset or maintenance

You may not qualify if…

• Any secondary RLS
• require treatment for daytime RLS symptoms
• symptomatic neuropathies

Where it is running

• Pfizer Investigational Site — Tuscaloosa, Alabama, United States
• Pfizer Investigational Site — Little Rock, Arkansas, United States
• Pfizer Investigational Site — San Diego, California, United States
• Pfizer Investigational Site — Santa Monica, California, United States
• Pfizer Investigational Site — Aurora, Colorado, United States
• Pfizer Investigational Site — Brandon, Florida, United States
• Pfizer Investigational Site — Macon, Georgia, United States
• Pfizer Investigational Site — Louisville, Kentucky, United States
• Pfizer Investigational Site — Baton Rouge, Louisiana, United States
• Pfizer Investigational Site — Raleigh, North Carolina, United States
• Pfizer Investigational Site — Salisbury, North Carolina, United States
• Pfizer Investigational Site — Winston-Salem, North Carolina, United States
• Pfizer Investigational Site — Oklahoma City, Oklahoma, United States
• Pfizer Investigational Site — Dallas, Texas, United States
• Pfizer Investigational Site — Alexandria, Virginia, United States
• Pfizer Investigational Site — Innsbruck, Austria
• Pfizer Investigational Site — Vienna, Austria
• Pfizer Investigational Site — Bad Saarow, Germany
• Pfizer Investigational Site — Berlin, Germany
• Pfizer Investigational Site — Göttingen, Germany
• Pfizer Investigational Site — Mittweida, Germany
• Pfizer Investigational Site — München, Germany
• Pfizer Investigational Site — Oldenburg, Germany
• Pfizer Investigational Site — Schwerin, Germany
• Pfizer Investigational Site — Madrid, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.